Silo Pharma Inc/$SILO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Silo Pharma Inc
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Ticker
$SILO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
3
ISIN
US82711P2011
Website
Silo Pharma Inc Metrics
BasicAdvanced
$4.5M
-
-$1.13
1.52
-
Price and volume
Market cap
$4.5M
Beta
1.52
52-week high
$1.45
52-week low
$0.41
Average daily volume
1.5M
Financial strength
Current ratio
4.728
Quick ratio
4.6
Interest coverage (TTM)
-931.88%
Profitability
Gross margin (TTM)
91.90%
Net profit margin (TTM)
-6,411.26%
Operating margin (TTM)
-6,824.27%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-47.90%
Return on equity (TTM)
-99.38%
Valuation
Price to revenue (TTM)
35.607
Price to book
0.7
Price to tangible book (TTM)
0.75
Price to free cash flow (TTM)
-0.554
Free cash flow yield (TTM)
-180.58%
Free cash flow per share (TTM)
-113.50%
Growth
Earnings per share change (TTM)
-5.37%
10-year revenue growth (CAGR)
11.08%
3-year earnings per share growth (CAGR)
-18.99%
10-year earnings per share growth (CAGR)
3.75%
Silo Pharma Inc News
AllArticlesVideos
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
GlobeNewsWire·5 days ago
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
GlobeNewsWire·2 weeks ago
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Silo Pharma Inc stock?
Silo Pharma Inc (SILO) has a market cap of $4.5M as of July 12, 2025.
What is the P/E ratio for Silo Pharma Inc stock?
The price to earnings (P/E) ratio for Silo Pharma Inc (SILO) stock is 0 as of July 12, 2025.
Does Silo Pharma Inc stock pay dividends?
No, Silo Pharma Inc (SILO) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Silo Pharma Inc dividend payment date?
Silo Pharma Inc (SILO) stock does not pay dividends to its shareholders.
What is the beta indicator for Silo Pharma Inc?
Silo Pharma Inc (SILO) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.